ABOUT Vivid Dx
Let’s Accelerate the Detection of Sepsis-Causing Pathogens and Antimicrobial Resistance (AMR)
Vivid Dx was founded to address one of healthcare’s most urgent and costly challenges: diagnostic delays that contribute to millions of sepsis-related deaths each year and accelerate the spread of antimicrobial resistance (AMR).
Our mission is to disrupt the multibillion-dollar blood culture-based diagnostics market with a next-generation platform that enables faster clinical decisions, improved patient outcomes, and substantial cost savings.
49M cases and 11M deaths annually – more than all cancers combined (WHO)
$62B spent annually in the U.S. on sepsis-related hospitalizations (HHS)
No rapid diagnostics – time to targeted treatment is the strongest predictor of survival
Sepsis
6M deaths per year from bacterial AMR (The Lancet)
>$1T in projected annual cost by 2050 due to AMR-driven healthcare burdens (World Bank)
Inadequate diagnostics fueling inappropriate antibiotic use and resistance
Antimicrobial Resistance (AMR)
Current Diagnostics Take Days
Every hour counts when treating bloodstream infections and sepsis — but current blood culture-based diagnostics take 2–4 days, forcing clinicians to use broad-spectrum antibiotics. Up to 70% of the time, broad-spectrum antibiotics are not optimal.
The result: longer hospital stays, higher costs, rising mortality, and worsening antimicrobial resistance.
Vivid Dx is changing that.
We plan to deliver broad pathogen ID in 30 minutes and phenotypic AST in 3 hours, enabling faster, targeted treatment decisions.
This isn’t just a clinical breakthrough — it’s a chance to improve outdated workflows and unlock substantial value in a multibillion-dollar diagnostics market. We believe patients deserve better — and providers need better tools to make faster, smarter decisions.
We Believe this is a Game-Changer…and a Guideline Changer
Vivid Dx is developing a next-generation diagnostic platform to deliver broad pathogen identification directly-from-blood in just 30 minutes, and phenotypic antibiotic susceptibility results in 3 hours, without the need to wait days for blood culture results. Our system combines a scalable Raman spectral database for comprehensive pathogen detection, advanced AI and machine learning for rapid interpretation, and microfluidics for phenotypic AST at unprecedented speed.
Grounded in peer-reviewed science, proprietary datasets, and early clinical validation, Vivid Dx is poised to redefine the standard of care for sepsis and antimicrobial resistance, while unlocking substantial value in a multibillion-dollar market.
Our Values
Urgency with Purpose
In the fight against sepsis and antimicrobial resistance, every hour counts. We innovate with urgency to deliver diagnostics that enable faster, more informed treatment decisions.
Integrity at Every Step
We hold ourselves to the highest ethical standards in our science, our partnerships, and our mission. Trust, transparency, and accountability are foundational to how we operate.
Science-Driven Innovation
We were born at the University of Oxford…We are relentless in pursuit of scientific excellence. Every decision is grounded in rigorous research, validated data, and a commitment to solving real-world clinical challenges.
Collaboration for Impact
We work across multiple disciplines — uniting clinicians, engineers, scientists, and partners — to accelerate progress and build solutions that no one could achieve alone.
Focused on Meaningful Outcomes
We are driven by a clear purpose: to improve patient outcomes, reduce cost, and reduce the threat of AMR. Everything we do is intended to make a measurable difference.